Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Vimseltinib |
| Trade Name | Romvimza |
| Synonyms | DCC-3014|DCC3014|DCC 3014|DP-6865 |
| Drug Descriptions |
Romvimza (vimseltinib) inhibits CSF1R, potentially resulting in increased anti-tumor immune response in combination with other agents (PMID: 29679908, PMID: 34433663). Romvimza (vimseltinib) is FDA-approved for use in patients with symptomatic tenosynovial giant cell tumor (FDA.gov). |
| DrugClasses | CSF1R Inhibitor 28 |
| CAS Registry Number | 1628606-05-2 |
| NCIT ID | C175876 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Avelumab + Vimseltinib | Avelumab Vimseltinib | 0 | 1 |
| unspecified PD-1 antibody + Vimseltinib | Vimseltinib unspecified PD-1 antibody | 0 | 0 |
| Vimseltinib | Vimseltinib | 0 | 2 |